SCHEMBL2335696

SCHEMBL2335696

O=C(O)c1cccnc1Oc1cc(Cl)ccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 9/20 0.60
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
RAB9A P51151 2/20 0.51
CCR2 P41597 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
ALDH1A1 P00352 2/20 0.47
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
MRGPRX4 Q96LA9 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MEN1 O00255 1/20 0.46
DHODH Q02127 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2336929 0.90 MRGPRX4 (0.54) GPBAR1RAB9ACCR2SMN1; SMN2LMNA
SCHEMBL2329971 0.89 GPBAR1 (0.60) GPBAR1CYP3A4CYP2C9RAB9AALDH1A1
SCHEMBL2784871 0.88 TTR (0.50) GPBAR1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL2780412 0.86 UGCG (0.49) GPBAR1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL2332795 0.85 TP53 (0.52) GPBAR1RAB9ACCR2SMN1; SMN2LMNA
SCHEMBL2779673 0.85 RAB9A (0.48) GPBAR1CYP2C9RAB9ACCR2SMN1; SMN2
SCHEMBL7431657 0.83 CCR2 (0.50) GPBAR1RAB9ACCR2SMN1; SMN2LMNA
SCHEMBL2783088 0.83 ALK (0.49) GPBAR1CYP3A4CYP2C9CCR2LMNA
SCHEMBL3137908 0.82 GPBAR1 (0.72) GPBAR1CYP3A4CYP2C9RAB9ASMN1; SMN2
SCHEMBL28484708 0.82 GPBAR1 (0.52) GPBAR1CYP3A4CYP2C9RAB9ACCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309734-B2 Substituted pyridines as GPBAR1 agonists HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2356094-A1 NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS F. Hoffmann-La Roche AG (CH) 2011-08-17 EP disclosed
WO-2010049302-A1 NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO disclosed
US-20100105906-A1 NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105906-A1 NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES GPBAR1, GPR119, GLP1R GPBAR1 1/4885CYP3A4 1330/4885CYP2C9 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.